Synsam AB (publ) (SYNSAM.ST)
SEK 42.3
(0.83%)
SEK 42.3
(0.83%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.52 Billion SEK | 1.58% |
| 2022 | 5.43 Billion SEK | 6.07% |
| 2021 | 5.12 Billion SEK | -41.99% |
| 2020 | 8.83 Billion SEK | 6.87% |
| 2019 | 8.26 Billion SEK | 8.54% |
| 2018 | 7.61 Billion SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 5.73 Billion SEK | 0.14% |
| 2024 Q1 | 5.73 Billion SEK | 3.79% |
| 2023 Q4 | 5.52 Billion SEK | -0.09% |
| 2023 Q2 | 5.79 Billion SEK | 2.06% |
| 2023 Q1 | 5.67 Billion SEK | 4.49% |
| 2023 Q3 | 5.52 Billion SEK | -4.66% |
| 2023 FY | 5.52 Billion SEK | 1.58% |
| 2022 Q4 | 5.43 Billion SEK | 0.57% |
| 2022 FY | 5.43 Billion SEK | 6.07% |
| 2022 Q3 | 5.4 Billion SEK | 0.8% |
| 2022 Q2 | 5.36 Billion SEK | 2.74% |
| 2022 Q1 | 5.21 Billion SEK | 1.83% |
| 2021 Q1 | 8.95 Billion SEK | 1.39% |
| 2021 Q4 | 5.12 Billion SEK | -43.55% |
| 2021 Q3 | 9.07 Billion SEK | 2.1% |
| 2021 Q2 | 8.89 Billion SEK | -0.73% |
| 2021 FY | 5.12 Billion SEK | -41.99% |
| 2020 FY | 8.83 Billion SEK | 6.87% |
| 2020 Q4 | 8.83 Billion SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 FY | 8.26 Billion SEK | 8.54% |
| 2018 FY | 7.61 Billion SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AddLife AB (publ) | 7.78 Billion SEK | 29.082% |
| Biotage AB (publ) | 1.27 Billion SEK | -333.359% |
| Bonesupport Holding AB (publ) | 143.63 Million SEK | -3743.664% |
| Doxa AB (publ) | 280.8 Million SEK | -1866.168% |
| Elekta AB (publ) | 21.61 Billion SEK | 74.462% |
| iZafe Group AB (publ) | 9.26 Million SEK | -59515.592% |
| Ortivus AB (publ) | 55.4 Million SEK | -9865.524% |
| Ortivus AB (publ) | 55.4 Million SEK | -9865.524% |
| Q-linea AB (publ) | 42.34 Million SEK | -12939.679% |
| S2Medical AB (publ) | 19.74 Million SEK | -27855.207% |